Showing results (1-10 of 311) with videos related to
Sort By:
Pageof 32
Diabetology & Metabolic Syndrome|October 30, 2012
Targeting adipose tissueBodo Haas, Paul Schlinkert, Peter Mayer, et al.European Journal of Clinical Pharmacology|April 24, 2014
Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerNiels Eckstein, Bodo HaasRegulatory Toxicology and Pharmacology : RTP|March 1, 2016
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissuesBodo Haas, Konstantin Weber-Lassalle, Roland Frötschl, et al.Orphanet Journal of Rare Diseases|August 6, 2014
Systemic therapy of Cushing's syndromeNiels Eckstein, Bodo Haas, Moritz David Sebastian Hass, et al.Journal of Cancer Research and Clinical Oncology|December 14, 2020
Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependentBodo Haas, Janine Ciftcioglu, Sanja Jermar, et al.International Journal of Molecular Sciences|September 26, 2018
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma CellsBodo Haas, Lena Schütte, Maria Wos-Maganga, et al.Journal of Experimental & Clinical Cancer Research : CR|February 8, 2014
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveNiels Eckstein, Lea Röper, Bodo Haas, et al.Journal of Experimental & Clinical Cancer Research : CR|October 5, 2011
Platinum resistance in breast and ovarian cancer cell linesNiels EcksteinScience Signaling|December 3, 2009
Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesisBodo Haas, Peter Mayer, Katja Jennissen, et al.Cancer Cell International|May 15, 2018
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugsBodo Haas, Veronika Klinger, Christina Keksel, et al.Pageof 32